Figures & data
Table 1 Clinicopathological Features of Breast Cancer Patients in GDPH and TCGA Databases
Figure 1 The mutation rates of AKT, AKT1, AKT2, and AKT3 in GDPH and TCGA cohorts of patients with breast cancer.
![Figure 1 The mutation rates of AKT, AKT1, AKT2, and AKT3 in GDPH and TCGA cohorts of patients with breast cancer.](/cms/asset/d81af31d-e501-434d-be99-7775f2639c74/dcmr_a_12189552_f0001_b.jpg)
Figure 2 The frequency of different mutation types of (A) AKT, (B) AKT1, AKT2, and AKT3 in the two cohorts.
![Figure 2 The frequency of different mutation types of (A) AKT, (B) AKT1, AKT2, and AKT3 in the two cohorts.](/cms/asset/a4afe959-dee3-4767-8ef4-9b0a0b69ec98/dcmr_a_12189552_f0002_b.jpg)
Figure 3 Diagram of domains of (A) AKT1, (B) AKT2 and (C) AKT3 with mutations identified in the GDPH cohort.
![Figure 3 Diagram of domains of (A) AKT1, (B) AKT2 and (C) AKT3 with mutations identified in the GDPH cohort.](/cms/asset/b44c0b0d-bc47-438f-8910-00335c43774a/dcmr_a_12189552_f0003_c.jpg)
Table 2 Correlation Between Clinicopathological Features and AKT Family Mutation in GDPH and TCGA Databases
Table 3 AKT Inhibitors in Clinical Development